You are here: Urology Textbook > Drugs in Urology > Alpha-blocker > Alfuzosin
Alpha-blocker (5/6): Alfuzosin
- Alpha-blocker (1/6): General pharmacology
- Alpha-blocker (2/6): Terazosin
- Alpha-blocker (3/6): Doxazosin
- Alpha-blocker (4/6): Tamsulosin
- Alpha-blocker (5/6): Alfuzosin
- Alpha-blocker (6/6): Silodosin
Review Literatur: (Chapple, 2004).
General Pharmacology of Alfuzosin
Please see section general pharmacology of alpha-blocker.
Mechanism of Action of Alfuzosin
Alfuzosin is a alpha1-blocker.
Indications for Alfuzosin
- Treatment of lower urinary tract symptoms due to benign prostatic hyperplasia
Pharmacokinetics of Alfuzosin
- Elimination half-life 9 h in retarded galenic formulation.
Alfuzosin: Mechanism of Action
Postsynaptic alpha1-blockade leads to:
- Smooth muscle relaxation of the prostate, bladder neck and the urethra. Alpha-blocker improve the dynamic component of subvesical obstruction due to benign prostatic hyperplasia.
General Side Effects of Alpha-Blocker
- Hypotension, orthostatic syncope, reflex tachycardia
- Stuffy nose
- Retrograde ejaculation
- Dizziness, weakness
- Overall rate of side effects is between 10–30%, selective alpha1A-blocker like alfuzosin have a reduced cardiovascular side effect rate.
Contraindications of Alfuzosin
Conservative treatment of BPH is not indicated, if surgical treatment is imperative: chronic urinary retention with renal failure, recurrent hematuria due to prostatic enlargement, recurrent infections and bladder stones.
Hypotension, mechanical heart failure (valvular, pulmonary embolism, pericarditis), congestive heart failure.
Alfuzosin should be paused perioperatively for cataract surgery to prevent an intraoperative floppy iris syndrome.
Dosage of Alfuzosin
10 mg in retarded galenic formulation 1–0–0 or 2.5 mg 1–1–1 or 5 mg 1–1–1
Index: 1–9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
- Chapple 2004 CHAPPLE, C. R.:
- Pharmacological therapy of benign prostatic hyperplasia/lower urinary
tract symptoms: an overview for the practising clinician.
In: BJU Int
94 (2004), Nr. 5, S. 738–44
Deutsche Version: Alfuzosin